Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary
Source: SeekingAlpha
2025-05-20 09:10:00 ET
Summary
- The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%.
- Positioning in biotechnology weighed on relative returns, while an underweight to life sciences tools and services contributed to performance.
- Despite near-term healthcare policy uncertainty, we believe the sector’s innovation remains intact and that its defensive qualities will continue to appeal to investors.
...
Read the full article on Seeking Alpha
For further details see:
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary
Janux Therapeutics Inc.
NASDAQ: JANX
JANX Trading
-2.82% G/L:
$13.605 Last:
326,754 Volume:
$14.06 Open:
JANX Latest News
February 26, 2026 04:01:00 pm
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 17, 2026 07:00:00 am
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
January 26, 2026 07:00:00 am
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
JANX Stock Data
$789,139,228
45,531,890
1.75%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
